Choong Ang Vaccine Laboratory Co. Ltd (072020) - Total Liabilities
Based on the latest financial reports, Choong Ang Vaccine Laboratory Co. Ltd (072020) has total liabilities worth ₩18.08 Billion KRW (≈ $12.25 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Choong Ang Vaccine Laboratory Co. Ltd to assess how effectively this company generates cash.
Choong Ang Vaccine Laboratory Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Choong Ang Vaccine Laboratory Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 072020 financial resilience to evaluate the company's liquid asset resilience ratio.
Choong Ang Vaccine Laboratory Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Choong Ang Vaccine Laboratory Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digital Multimedia Technology Co.Ltd
KQ:134580
|
Korea | ₩27.79 Billion |
|
Park Elektrik Uretim Madencilik Sanayi ve Ticaret AS
IS:PRKME
|
Turkey | TL578.29 Million |
|
FineMat Applied Materials Co Ltd
TW:6698
|
Taiwan | NT$963.77 Million |
|
Yatra Online Inc
NASDAQ:YTRA
|
USA | $5.56 Billion |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
India | Rs3.23 Billion |
|
Fluence Corporation Ltd
AU:FLC
|
Australia | AU$121.17 Million |
|
Kingstate Electronics
TWO:3206
|
Taiwan | NT$1.54 Billion |
|
Southland Holdings Inc.
NYSE MKT:SLND
|
USA | $1.05 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Choong Ang Vaccine Laboratory Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Choong Ang Vaccine Laboratory Co. Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Choong Ang Vaccine Laboratory Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Choong Ang Vaccine Laboratory Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Choong Ang Vaccine Laboratory Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩19.41 Billion ≈ $13.15 Million |
-1.92% |
| 2023-12-31 | ₩19.79 Billion ≈ $13.41 Million |
+1.20% |
| 2022-12-31 | ₩19.55 Billion ≈ $13.25 Million |
-2.11% |
| 2021-12-31 | ₩19.98 Billion ≈ $13.54 Million |
+14.61% |
| 2020-12-31 | ₩17.43 Billion ≈ $11.81 Million |
+70.87% |
| 2019-12-31 | ₩10.20 Billion ≈ $6.91 Million |
-13.11% |
| 2018-12-31 | ₩11.74 Billion ≈ $7.96 Million |
-30.73% |
| 2017-12-31 | ₩16.95 Billion ≈ $11.49 Million |
+28.61% |
| 2016-12-31 | ₩13.18 Billion ≈ $8.93 Million |
+82.46% |
| 2015-12-31 | ₩7.22 Billion ≈ $4.89 Million |
-16.11% |
| 2014-12-31 | ₩8.61 Billion ≈ $5.83 Million |
-- |
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Ko… Read more